MedPath

Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal disseminatio

Phase 1
Conditions
Gastric cancer with peritoneal dissemination
Registration Number
JPRN-UMIN000018658
Lead Sponsor
The Jikei University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions (such as pulmonary fibrosis, active infection, uncontrollable heart disease, uncontrollable diabetes mellitus, history of severe drug allergy).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the safety and determine RD
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath